Understanding how ATR signaling affects cancer treatment effectiveness
Official title: Uncovering ATR signaling networks underlying chemotherapeutic synergies
Funded at Cornell University · NIH-10913308 · Data updated 2026-11-12
This study is looking at how a special protein called ATR can help make certain cancer treatments work better together, especially for patients whose cancers don’t respond well to regular therapies, with the hope of finding new ways to improve their treatment.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cornell University NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $45,454 |
| NIH project number | 5F31CA281247-02 |
| Project ID | NIH-10913308 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that are known to be treated with ATR inhibitors and experience replication stress, such as colon cancer.
✕Less likely to help
Patients with cancers that do not involve ATR signaling or those who are not receiving chemotherapy may not benefit from this research.
What this research studies
This research investigates the role of ATR, a key protein involved in DNA damage response, in enhancing the effectiveness of certain cancer treatments. By using advanced techniques like mass spectrometry, the study aims to uncover the complex signaling networks activated in cancer cells when treated with specific chemotherapeutic agents. The goal is to identify how these treatments can work better together, particularly for cancers that show resistance to standard therapies. Patients may benefit from insights that could lead to more effective combination therapies for their cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment strategies that enhance the effectiveness of existing therapies.
How similar studies have gone: Other research has shown promising results in targeting ATR signaling in cancer therapy, indicating that this approach has potential for success.
Where this research is happening
-
Cornell University
Ithaca, United States Active
Researchers
- Principal investigator: Comstock, William — Cornell University
- Study coordinator: Comstock, William
Related research
Other NIH-funded projects on the same topics.
-
PORTENT 3.0 Technical Core for global health point-of-care tools
A NIH U54 grant supports Cornell and partners in advancing point-of-care technologies for nutrition, infection, and cancer to real-world use, especially in global health settings.
-
Point-of-care zinc test strips to verify infant zinc medicines in low-resource settings
A fast, low-cost smartphone‑based test strips method checks zinc-containing infant medicines in places with limited lab access.
-
Center for Spillover Prevention and One Health Readiness in Asia
A center in Asia works to prevent pandemics by studying how animal infections jump to humans and by building tools to detect and respond quickly to spillovers.
-
SAGE: A privacy-friendly system to monitor antimicrobial use in animals
A nationwide, privacy-preserving data hub will securely collect and standardize antimicrobial use data across animal species to support smarter stewardship and regulatory science.
-
Rapid, bedside KS diagnosis in Africa with KS-COMPLETE
A fast, point-of-care test using skin biopsies to diagnose Kaposi’s sarcoma in sub-Saharan Africa, helping patients get results in about an hour.
-
Nuclear mechanics in tight cell movement
Scientists are studying how the nucleus changes its shape and function when cells squeeze through very small spaces, which could affect health and disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.